• Skip to main content
  • Skip to primary sidebar

Gold Coast Health & Knowledge Precinct

Transform with us

  • Home
  • About Us
    • Strategic Plan
    • Partners
      • City of Gold Coast
      • Griffith University
      • Gold Coast Health
      • Economic Development Queensland
      • Gold Coast Private Hospital
      • Cohort
      • Southport Sharks
    • Our people
    • Precinct Office
    • Map
    • Contact Us
  • Do Business
    • Investment Incentives
  • Live & Play
    • Australia’s Gold Coast
    • Residential – Smith Collective
    • Lifestyle – Retail and Recreation
  • Work & Study
  • Projects
    • Projects Overview
    • ADaPT
    • Clinical Entrepreneurship Change Agents Program
    • NeuTex Image-guided Surgery and Robotics Training Centre
  • Research
    • Overview
      • Additive Manufacturing
      • Biotechnologies
    • Research Institutes and Centres
    • Precinct experts
    • Research Equipment & Facilities
    • Clinical Trials
    • Health and medical training and conference hub
  • News
    • Latest News
    • Newsletter
    • Media
    • Video Channel
  • 中文
    • English
    • 中文

Filed Under: BUSINESS, HEALTH, TECHNOLOGY Tagged With: Griffith University, healthtech, LuminaX

Griffith University team win top prize at 2023 LuminaX HealthTech Accelerator

After 14 weeks, 20 workshops, 300 hours of mentoring with 30+ mentors and a whole lot of support, 10 gamechanging healthtech startups hit the stage to pitch their businesses in front of more than 200 members of the GCHKP innovation ecosystem at LuminaX 2023 Demo Night.

And from an impressive lineup of commercial concepts to improve patient safety, provide VR treatment for complex mental health conditions, streamline nurse recruitment, revolutionise treatment for children with lower limb deformities and more, a trio of Griffith University researchers were named Startup of the Year for YourTrack, a neurodevelopmental assessment tool for children needing developmental support.

LuminaX Director Dren Xerxa with the YourTrack team: Professor Dianne Shanley, Dr Erinn Hawkins and Dr Wei Lui

Backed by extensive research and with a vision to be powered by AI, YourTrack was developed to track and triage children aged 0-17 years who have developmental concerns. The technology puts neurodevelopmental assessment in the hands of everyday health providers such as GPs and nurses, starting assessment and support earlier, rather than having to wait to rely on specialist paediatricians to assess vulnerable children who are falling behind.

Other clinical assessment tools are largely applicable to young children, but the YourTrack system works for children and adolescents while also providing a greater degree of insight into the extent of a child’s developmental delays.

YourTrack harnesses the power of local health providers so that kids can be ‘diagnosed faster, supported sooner’ and is set to do just that through the commercial acceleration the team achieved through LuminaX.

Professor Dianne Shanley, a clinical psychologist and prominent expert in health service delivery, says the team is excited to have a path towards sharing commercial proceeds from their clinical assessment tool with the community who helped design it.

“The LuminaX journey has been one of the most memorable and engaging learning experiences and we’re so thrilled and surprised to receive the award,” says Professor Shanley.

“The mentoring has helped us to develop a commercial pathway for organisations across the country to access what we’ve co-designed through our research.”

YourTrack Research Manager Dr Wei Liu says LuminaX was invaluable in honing the team’s understanding of customers.

“We reformed our pitch deck, developed our business model and “go to market” strategies, as well as rebranded our logo and website,” says Dr Liu.

“The biggest lesson I learned is to spend time with customers to understand what they want, not what we think they want. Then we present our products as either solving their problems or fulfilling their needs instead of “hard selling” what we have created. 

“We’ve successfully attracted several new customers by using this method.” 

Dr Erinn Hawkins, who co-developed part of the tracking system with a team in Bangladesh, says they now feel confident to work with partners to make YourTrack Developmental Tracking Systems the most trusted developmental assessment system on the market.

“We believe we can now translate our research outcomes into a commercial product that will help us reach and support the more than one million Australian children with developmental vulnerabilities,” she says.

Alignus team aid surgeries during LuminaX
Dr Martina Barzan delivers the Alignus pitch

For the second Griffith University team in the program, biomedical engineer Dr Martina Barzan and clinical researcher Associate Professor Chris Carty of Alignus, LuminaX provided a boost towards the commercial rollout of their world-leading surgery simulation technology to aid orthopaedic surgeries, starting with paediatric patients.

Even during the busy LuminaX program, Dr Barzan worked with surgeons to plan and execute two complex orthopaedic surgeries, taking the total of successful procedures performed with their products to almost 30.

“[In LuminaX] we had access to industry leaders in product development, brand identity and financial modelling, and with the support of the expert LuminaX team, we were able to prepare a compelling pitch that is already attracting investment interest, “says Associate Professor Carty.

“Our next step is to partner with like-minded investors to secure regulatory approval for Alignus products by the end of 2024.”

LuminaX Fan Fave winner optimises nurse recruitment

For nurse Anna Lumb, relocating to Brisbane and searching for the right job sparked her idea to create a dedicated careers marketplace for what she call’s Australia’s almost half-a-million strong “nurseforce”.

Anna Lumb of Nursify won the Fans Fave Award

Struck by the irony of working in Australia’s most sought-after profession but being unable to connect directly with hospitals to find the right role, Nursify was born. One of six female founders to pitch during the slick Demo Night at Miami Marketta, Lumb was judged ‘Fans Fave’.

LuminaX is a 14-week program that validates and commercialises selected early-stage, high-growth activities applying tech or AI solutions to healthcare, medtech and wellness. Developed and delivered by Cohort Innovation Space, it has the support of major partners the Queensland Government (through Economic Development Queensland and Advance Queensland) and City of Gold Coast.

Griffith University, Mater Hospital, the Queensland AI Hub and IntelliHQ are onboard as industry partners.

Cohort has the full event livestream here.


August 2, 2023 By Kathy Kruger

Filed Under: BUSINESS, INVEST, TECHNOLOGY

International MedTech company joins GCHKP ecosystem

With a vision of the Gold Coast as a leading global centre for endovascular R&D and training, neurovascular device company Wallaby-phenox  (Wallaby, phenox) has based its Vice President for international direct markets, including Asia-Pacific, Latin America and the Middle East, in a new office in the Gold Coast Health and Knowledge Precinct.

The US/Chinese/German-operated company will leverage recent investment by Doctors Hal Rice and Laetitia de Villiers in their world-first NeuTex Image-guided surgery and robotics training centre, in partnership with global medical leader Philips, to stage global expansion in treatments for stroke and other conditions.

A 20-year-veteran of the medical device industry with a passion for the life-saving potential of neuro-interventional technologies, Wallaby-phenox’s Kirk Slater has never been more excited at the opportunity to save lives and reduce disability through minimally-invasive endovascular procedures.

And he loves that he can achieve global impact from his adopted home on the Gold Coast.

“The Gold Coast is a great location to access the Asia-Pacific, but the unique value is the opportunity to work closely with NeuTex and doctors Rice and de Villiers, who I’ve known and worked with as leading innovators for 15 years,” Kirk says.

Originally from South Africa and having worked for both major and smaller MedTech companies in Australia and New Zealand, Kirk is relishing a return to a smaller company with a growing global reach, accelerated when Wallaby Medical, jointly based in the US and China, acquired German neuro-interventional leader phenox in April 2022.

Their portfolio of medical products now includes catheters, coil systems and flow modulation devices, with 5 R&D centers, 3 production bases, over 700 employees worldwide, and more than 350 global patents granted or pending.

“I like building things and being an underdog,” Kirk says.

“In this role, I have the opportunity to be creative and disruptive, and we need innovation if we are to substantially increase endovascular treatment for stroke over the prevailing protocol of clot-busting drugs, which unfortunately leaves some patients clinically excluded from treatment due to time-sensitivity and underlying conditions.”

Kirk stresses that it’s not a battle of drugs vs devices, but an opportunity to continue to evolve endovascular treatments to achieve broader reach by taking a ‘value-based’ healthcare approach.

“When considering treatment options and costs we want to be evaluating what one ‘quality life year’ is worth to the individual and society – stroke unfortunately still causes a lot of disability,” he says.

 

Specialist training fellows in the NeuTex Image-Guided Therapy Surgery and Robotics Training Centre which opened in May 2023

The neurovascular field has led the way in minimally-invasive image-guided interventions, treating strokes and brain aneurysms by feeding tiny devices such as coils and stents into the brain through fine catheters to repair blockages. The future includes treating patients with neurodegenerative conditions using implantable devices.

Kirk with Wallaby-phenox President Global Commercial Peter Cooke (second from right) with BirdDog and Remedi CEO Dan Miall (left) and Medical Innovation Manager Ben Wills (right)

Beyond conditions in the brain, innovation in cardiovascular, peripheral vascular, spinal and renal treatments using catheters and devices present the opportunity to help many more patients.

“The Neurovascular device market is worth $4-5 billion worldwide, compared to the $60 billion global cardiology market, which shows the order of magnitude of patients that innovation in cardiology could serve.”

Kirk plans to grow a team of 6 based at Cohort Innovation Space, with the same number based across Australia within the next few years.

He’ll concentrate on opening up the Indian market and the broader Asia-Pacific region, as well as direct entry into Latin America – a big brief that requires long days and nights to accommodate different timezones.

Equally, he’s focused on what comes next – innovation in catheter designs that are thinner and more durable – and next-generation training, partnering with NeuTex and their technology partner BirdDog, an Australian ASX-listed company that provides high-fidelity video capture and software to enable remote proctoring.

“We want to be the first neurovascular device company to deliver truly global workshops via high-quality video links that provide realistic experiences for trainees in multiple locations at once,” Kirk says.

“One day we hope that will extend to using robotics to enable cross-border procedures, where expert clinicians can collaborate to treat complex cases.”

June 22, 2023 By Kathy Kruger

Filed Under: HEALTH, TECHNOLOGY Tagged With: artificial heart, BiVACOR, Cohort, Griffith Mechanobiology Lab, Griffith University, Medtech

BiVACOR wins new grant for artificial heart development

BiVACOR researchers in the Precinct will focus on a next-generation external device controller as part of their development of a world-first Total Artificial Heart (TAH), supported by a $750k grant from the Australian Government through its Medical Research Future Fund (MRFF) and Targeted Translation Research Accelerator (TTRA) program.

As the company heads towards first-in-human clinical trials within the next two years, the grant, matched by in-kind support bringing approximately AUD$2.2 million in funding towards BiVACOR’s clinical advancement, will help develop a lighter, smaller, more portable external controller to give patients better quality of life at home.

External heart controller development to improve patient comfort

BiVACOR’s novel TAH technology is the first long-term therapy dedicated to patients with severe biventricular heart failure.

The implantable total artificial heart, the size of a human fist, is based on a rotary blood pump and uses magnetic levitation (MAGLEV) technology to enable the double-sided centrifugal impeller to rotate in free-space, minimising blood trauma and eliminating mechanical wear.

Dr Daniel Timms with the BiVACOR TAH

A long labour of love for founder and Chief Technology Officer (CTO) Dr Daniel Timms, the BiVACOR TAH has enjoyed significant Australian government support over its two decades of R&D.

“Heart failure hits close to home for me. It remains a leading cause of death worldwide, and its prevalence is only increasing,” says Dr Timms, who lost his father to the disease.

 “BiVACOR is an Australian-born innovation, and we are extremely grateful for the ongoing support from the Australian government and community.

Without their support, we wouldn’t be where we are today, and this grant gives us a boost in the clinic to drill down into the TAH external controller.”

The TTRA program, a MRFF initiative delivered by MTPConnect, supports new approaches to improve the prevention, dianosis, treatment and management of diabetes and cardiovascular disease complications.

Griffith researchers work on testing the BiVACOR TAH for its blood compatibility

While the implantable device is largely being developed in the US, including through collaboration with the Texas Heart Institute, the latest version heading towards clinical trials has been extensively tested at Griffith University’s Mechanobiology lab, with the aim of understanding and reducing its impact on blood cells.

Across the road at Cohort, where BiVACOR bases its international office, research engineers are focused on the heart’s external controller and its software.

“We want a controller that is as small, lightweight and as ergonomic as possible to maximise portability and comfort,” explains Dr Timms.

“At the same time, it needs to be totally reliable, including its batteries and power system, and we want to create a software interface that enables patients to easily monitor and manage their cardiovascular health, while providing timely and reliable data and alerts to their clinicians when needed.”

During the planned first-in-human trials, patients implanted with the TAH will remain in hospital for monitoring, whilst waiting for a human heart transplant.

“Our goal is to provide the best possible solution for patients facing end-stage heart failure who have run out of options,” says BiVACOR CEO Dr Thomas Vassiliades.

“These funds will give us a clinical advantage as we push on perfecting the external controller for the TAH.”

The BiVACOR TAH builds on the successful transition of Left Ventricular Assist Device (LVAD) technology from volume displacement to durable rotary blood pumps and aims to be the next-generation TAH that sufficiently restores quality of life to patients suffering from severe biventricular heart failure.

The TAH therapy may be initially utilised as a short-term device in a patient awaiting a heart transplant or as a long-term alternative to heart transplantation.

To date, BiVACOR has raised more than AUD$50 million in funding.

February 8, 2023 By Kathy Kruger

  • « Go to Previous Page
  • Page 1
  • Interim pages omitted …
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Interim pages omitted …
  • Page 14
  • Go to Next Page »

Primary Sidebar

Recent Posts

  • From Research to Reality: GCHKP Talent Leads the LuminaX 2025 Cohort
  • A New Era of Health and Tech Innovation: HATRIC to Transform the Gold Coast
  • Clinician Entrepreneurship Program wraps as a big success
  • 2025 International Women’s Day
  • International Women’s Day event 2025
  • Associate Prof Lara Herrero leading the fight against mosquito-borne diseases and advancing medical research
  • INVEST-FEST accelerates founder funding
  • Student innovation incubator set to launch in 2025
  • World-first clinical trial for treating spinal cord injury
  • Australian-designed Total Artificial Heart amongst The Australian’s Top 100

Archives

  • April 2025
  • March 2025
  • February 2025
  • November 2024
  • October 2024
  • September 2024
  • July 2024
  • May 2024
  • April 2024
  • January 2024
  • December 2023
  • October 2023
  • September 2023
  • August 2023
  • June 2023
  • May 2023
  • April 2023
  • March 2023
  • February 2023
  • October 2022
  • August 2022
  • July 2022
  • May 2022
  • March 2022
  • February 2022
  • November 2021
  • October 2021
  • August 2021
  • July 2021
  • May 2021
  • April 2021
  • March 2021
  • February 2021
  • January 2021
  • December 2020
  • November 2020
  • October 2020
  • September 2020
  • August 2020
  • July 2020
  • June 2020
  • May 2020
  • March 2020
  • February 2020
  • December 2019
  • October 2019
  • September 2019
  • August 2019
  • July 2019
  • June 2019
  • May 2019
  • April 2019
  • March 2019
  • January 2019
  • December 2018
  • October 2018
  • August 2018

Subscribe to our newsletter and we’ll update you on all that’s new in our Precinct.

Latest News

From Research to Reality: GCHKP Talent Leads the LuminaX 2025 Cohort image

From Research to Reality: GCHKP Talent Leads the LuminaX 2025 Cohort

Read More >

A New Era of Health and Tech Innovation: HATRIC to Transform the Gold Coast image

A New Era of Health and Tech Innovation: HATRIC to Transform the Gold Coast

Read More >

Clinician Entrepreneurship Program wraps as a big success image

Clinician Entrepreneurship Program wraps as a big success

Read More >

2025 International Women's Day image

2025 International Women's Day

Read More >

International Women's Day event 2025 image

International Women's Day event 2025

Read More >

Associate Prof Lara Herrero leading the fight against mosquito-borne diseases and advancing medical research image

Associate Prof Lara Herrero leading the fight against mosquito-borne diseases and advancing medical research

Read More >

Before Footer

Search

Asia-Pacific’s emerging health and innovation hub, the 200-hectare Gold Coast Health & Knowledge Precinct (GCHKP) is a unique global business location for high-tech industry development, research collaboration and jobs of the future.

  • Home
  • About Us
  • Precinct Map
  • News
  • Do Business
  • Work & Study
  • Partners
  • Projects
  • Research
  • Contact Us
  • Privacy Policy
  • Sitemap
  • Subscribe
  • Facebook
  • LinkedIn
  • YouTube

© 2025 Gold Coast Health and Knowledge Precinct. All rights reserved.

Designed and Developed by Stead Lane